Biocon Biologics Prepares for Launch of New Biosimilars
Biocon Biologics Ltd. (BBL), a prominent name in the global biosimilars landscape, has reached a pivotal milestone with its settlement and licensing agreement with Amgen Inc. This landmark arrangement is set to facilitate the entry of two significant biosimilars, Bosaya™ and Aukelso™, into the U.S. market, advancing opportunities for patients and healthcare providers alike.
Both Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab-kyqq), positioned as alternatives to Amgen's widely recognized Prolia® and Xgeva®, aim to address critical health issues associated with osteoporosis and cancer-related bone disorders. The anticipated launch on October 1, 2025, marks an essential step towards facilitating broader access to essential treatments for patients in the United States.
Settlement Agreement Promotes Patient Access
The agreement with Amgen resolves pending patent litigation in the United States District Court for the District of New Jersey, creating a clear pathway for Biocon Biologics to introduce these innovative biosimilars. Shreehas Tambe, CEO & Managing Director of Biocon Biologics, emphasized the significance of this settlement, stating that it will facilitate the provision of high-quality denosumab biosimilars to patients, reinforcing the company’s commitment to enhancing access to vital biologic medicines across various therapeutic areas.
The U.S. Food and Drug Administration (FDA) has previously approved both Bosaya™ and Aukelso™, reflecting their established safety and efficacy levels. In addition to the approval, both products have been recognized with provisional interchangeability designations, further enhancing their credibility in the market.
Applications and Efficacy of Bosaya™ and Aukelso™
Bosaya™ has been approved for multiple indications, including treating postmenopausal osteoporosis in women at high fracture risk, and creating bone mass in men with osteoporosis, as well as in those receiving androgen deprivation therapy for nonmetastatic prostate cancer. It significantly reduces fracture risks in individuals undergoing treatments that may compromise bone health.
Aukelso™ focuses on preventing skeletal-related events in patients with conditions such as multiple myeloma and those with solid tumors that have metastasized to bones. Additionally, it provides treatment options for young patients with giant cell tumor of bone—a challenging case that often requires exhaustive treatment protocols.
The Science Behind Denosumab
Both Bosaya™ and Aukelso™ feature denosumab as their active ingredient—a human monoclonal antibody effective in inhibiting Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), a vital component in bone resorption. By targeting RANKL, these biosimilars foster improved bone mass and strength, presenting a significant advancement in managing bone health.
Broader Implications in Healthcare
Osteoporosis affects millions of adults in the U.S., with over 10 million diagnosed and an additional 44 million at risk. This chronic condition remains a leading cause of fractures among older adults, underlining the importance of innovative treatments like Bosaya™ and Aukelso™. Furthermore, as oncology treatments evolve, preventing skeletal complications in patients with metastatic diseases becomes crucial in improving overall healthcare outcomes.
The emergence of giant cell tumors also poses unique challenges, especially given their prevalence in younger demographics. Biocon Biologics is committed to advancing treatment frameworks that enhance life quality for such patients, with a clear focus on safety and efficacy.
Commitment to Excellence and Sustainability
As a fully integrated biosimilars company, Biocon Biologics is dedicated to serving patients across over 120 countries. By advancing its portfolio of biosimilars, the company aims to ensure patient access to affordable, high-quality therapies. Its commitment extends beyond biosimilars to environmental and social governance, with recognition in the S&P Global Sustainability Yearbook for its efforts in promoting health for the planet and its people.
The company’s proactive nature in addressing both healthcare needs and environmental challenges demonstrates a model for future healthcare enterprises striving for excellence and sustainability. With many biosimilar assets under development, Biocon Biologics stands at the forefront of addressing chronic health conditions effectively and responsibly.
Frequently Asked Questions
What are Bosaya™ and Aukelso™?
Bosaya™ and Aukelso™ are denosumab biosimilars developed by Biocon Biologics for treating osteoporosis and preventing skeletal-related events in bone cancer patients.
When will these products be launched in the U.S.?
Both Bosaya™ and Aukelso™ are scheduled for launch on October 1, 2025.
What are the benefits of using these biosimilars?
These biosimilars provide effective treatment options for osteoporosis and bone health, particularly beneficial for patients at high risk of fractures.
How does denosumab work in these treatments?
Denosumab targets RANKL, inhibiting bone resorption and promoting bone density, which helps reduce fracture risks.
What is Biocon Biologics' mission?
Biocon Biologics aims to transform healthcare by providing affordable access to biologic therapies that improve patients' lives globally.
